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ABSTRACT  37 
In this placebo-controlled phase II randomized clinical trial, 103 HIV-1 infected 38 
patients under c-ART (combined antiretroviral treatment) were randomized 2:1 to 39 
receive 3 doses of DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag and 40 
gp160) at Week (W)0, W4 and W12 followed by 2 doses of LIPO-5 vaccine 41 
containing long peptides from Gag, Pol and Nef at W20 and W24 or placebos. 42 
Analytical treatment interruption (ATI) was performed between W36 to W48. 43 
At W28, vaccinees experienced an increase in functional CD4+ T cell responses 44 
measured (P<0.001 for each cytokine compared to W0) predominantly against 45 
Gag and Pol/Env and an increase in HIV-specific CD8+ T cells producing IL-2 46 
and TNF-α (P=0.001 and 0.013, respectively), predominantly against Pol/Env 47 
and Nef. However, analysis of T cell subsets by mass cytometry in a 48 
subpopulation showed an increase of W28/W0 ratio for memory CD8+ T cells co-49 
expressing exhaustion and senescence markers such as PD-1/TIGIT (P=0.004) 50 
and CD27/CD57 (P=0.044) in vaccinees compared to placebo. During ATI, all 51 
patients experienced viral rebound with a maximum observed HIV RNA level at 52 
W42 (median: 4.63 log10 cp/ml; IQR 4.00-5.09) without any difference between 53 
arms. No patient resumed c-ART for CD4 cell count drop. Globally, the vaccine 54 
strategy was safe. However, a secondary HIV transmission during ATI was 55 
observed. 56 
These data show that the prime-boost combination of DNA and LIPO-5 vaccines 57 
elicited broad and polyfunctional T cells. The contrast between the quality of 58 
immune responses and the lack of potent viral control underscores the need of 59 
combined immunomodulatory strategies.  60 
 on A









In this placebo-controlled phase II randomized clinical trial, we evaluated the 62 
safety and immunogenicity of a therapeutic prime-boost vaccine strategy using a 63 
recombinant DNA vaccine (GTU®-MultiHIV B clade) followed by a boost 64 
vaccination by a lipopeptide vaccine (HIV-LIPO-5) in HIV-infected patients while 65 
on combined antiretroviral therapy. We show that this prime-boost strategy is well 66 
tolerated, consistently with previous studies in HIV-1 infected individuals and 67 
healthy volunteers who received each vaccine component individually. 68 
Compared to placebo group, vaccines elicited strong and polyfunctional HIV-69 
specific CD4+ and CD8+ T cell responses. However, these immune responses 70 
presenting some qualitative defects were not able to control viremia following 71 
antiretroviral treatment interruption as no difference in HIV viral rebound was 72 
observed in vaccine and placebo groups. Several lessons were learned from 73 
these results pointing out the urgent need to combine the vaccine strategies with 74 
other immune-based interventions. 75 
 76 
  77 
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Despite the beneficial effects of cART on HIV morbidity and mortality, these 79 
drugs do not eradicate the latent HIV reservoir resulting in a constant rebound in 80 
viremia after stopping cART (1). Several strategies are under development to 81 
clear latently infected cells, which contain integrated HIV DNA, capable to survive 82 
indefinitely in patients despite long-term cART. The concept behind these 83 
strategies, which needs to be proven, is that activation of these cells using 84 
latency reversing agents for instance, may lead to HIV reactivation, expression of 85 
HIV proteins and elimination of these cells by the immune system (2). Until now, 86 
clinical outcomes using this strategy have been disappointing. One possible 87 
obstacle is that the killing of cells harboring HIV requires robust and efficient T-88 
cell responses making therapeutic vaccination central in strategies aiming at 89 
reducing the latent HIV reservoir and at achieving a functional cure (3).  90 
 91 
In the last 25 years, several vaccine strategies to restore and improve HIV-92 
specific functional immune responses have been developed, with varying results 93 
in terms of immunogenicity or HIV control when experimental designs comprised 94 
a period of ART interruption. In some trials, a partial effect on viral rebound was 95 
observed (4). Although promising, firm conclusions on the efficacy of these 96 
strategies are difficult to draw when they are based on non-controlled studies (4). 97 
 98 
In the present study, we sought to address some of these issues by designing a 99 
randomized, placebo-controlled therapeutic vaccination trial combining two 100 
different HIV vaccines, GTU®-MultiHIV B clade and long HIV lipopeptide 101 
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sequences (HIV LIPO-5 vaccine) in a prime-boost regimen. These two vaccines 102 
share homologous HIV sequences and strong CTL epitopes. The GTU®-103 
MultiHIV B encodes for a MultiHIV antigen (Rev, Nef, Tat, Gag p17/p24 proteins 104 
and an epitope stretch of previously identified CTL epitope-rich regions encoded 105 
by pol and env of a subtype B HIV-1 isolate Han-2) and lipopeptides are 106 
composed of 5 synthetic peptides (Nef 66-97, Nef 116-145, Gag 17-35, Gag 253-107 
284, Pol 325-355 also from a clade B strain) to which lipid chains are covalently 108 
bound. GTU®-MultiHIV B has been evaluated in HIV untreated patients where it 109 
led to HIV-specific sustained CD4+ and CD8+ T cell response as well as a 110 
significant decline of plasma HIV viral load (5). More recent results combining 111 
transcutaneous (TC) and intramuscular (IM) injection of GTU®-MultiHIV B 112 
showed a lack of improvement of immune responses in HIV treated patients and 113 
concluded for the need of a combinatory approach (6). LIPO-5 has been 114 
evaluated in healthy adults where it led to a sustained HIV-specific CD4+ and 115 
CD8+ T-cell responses (7, 8).  116 
Correlates of protection/control/cure are supposed to be different from HIV 117 
prophylactic interventions and especially T cell responses are supposed to play a 118 
key role in the clearance of infected cells. Successful approaches in SIV such as 119 
the CMV-based vaccine have given new bases on the key role of CD8+ T cell 120 
response (9). There is a consensus in the field to propose ATI for evaluation of 121 
the virological efficiency of an immune intervention on the HIV reservoir since the 122 
ultimate objective of any intervention in HIV treated patients is to maintain a low 123 
viral replication after cART withdrawal (10). The efficacy endpoints of our study 124 
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included T-cell immunogenicity and viral kinetics following a 12-week period of 125 
antiretroviral treatment interruption (ATI).  126 
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Study participants 128 
One hundred and thirty-three HIV-infected individuals were screened, and 103 129 
were enrolled and randomized in 18 centers in France between September 2013 130 
and May 2015 (Figure 1B). Five participants withdrew consent before receiving 131 
any intervention, 98 received at least one injection of placebo (n=35) or vaccine 132 
strategy (n=63) and were included in the mITT analysis of the study. Baseline 133 
characteristics of participants are reported in Table 1. The two study arms were 134 
balanced at baseline. Nine participants (2 and 7 in placebo and vaccine groups, 135 
respectively) withdrew from further follow up after week 0, the majority due to 136 
consent withdrawal. 137 
 138 
Global overview of vaccine immunogenicity  139 
Evaluation of vaccine-elicited T cell responses measured by flow cytometry-140 
based intracellular cytokine staining (ICS) for antigen-specific IFN-γ and/or IL-2 141 
and/or TNF-α was performed at baseline and week 28 on ninety-two participants 142 
who received the complete schedule of vaccination/placebo until week 28 in a 143 
per protocol analysis. Total CD4+ T cell responses to several HIV peptides pools 144 
showed no difference between groups at entry. We found a significant increase 145 
of CD4+ T cells producing cytokines to HIV peptide pools in the vaccine group at 146 
week 28 compared to baseline (P<0.001) while no difference was observed in 147 
the placebo group (Figure 2A). Detailed analysis for each cytokine and each HIV 148 
peptide pool showed a significant increase in IFN-γ, IL-2 and TNF-α production 149 
after Gag and Pol/Env stimulation, but not Nef, in the vaccine group (Figure 2C) 150 
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as well as increases of CD4+ T cells producing 1, 2 or 3 cytokines at W28 151 
(P<0.001 for all comparisons to baseline) (Figure 2D), specially against Gag and 152 
Pol/Env pools (P<0.001 for each comparison) (Figure 2F). While CD8+ T cells 153 
producing cytokines against HIV peptides did not change in the placebo group, 154 
we found an increase of total cytokine in the vaccine group at week 28 compared 155 
to baseline (Figure 2B), and detailed analysis showed that these responses were 156 
directed against Pol/Env and Nef peptides, but not Gag (Figure 2C). The 157 
frequency of polyfunctional CD8+ T cells (producing at least 2 cytokines), but not 158 
of monofunctional CD3+CD8+ T cells (producing only 1 cytokine), increases 159 
significantly in the vaccine group compared to W0 (P=0.04 and 0.025 for 160 
production of 2 and 3 cytokines, respectively) (Figure 2E), especially after 161 
Pol/Env or Nef stimulation (Figure 2F).  162 
To extend the analysis of immune cells, an ancillary analysis of T cell phenotypic 163 
profile was performed in 28 patients (12 placebo and 16 vaccinees) with mass 164 
cytometry allowing the detection of 40 cell surface markers. Figure 3 depicts the 165 
W28/W0 ratio of gated positive populations for each marker in vaccinees 166 
compared to placebo. Significant changes of CD8+ memory T cell subsets were 167 
observed in the vaccine group after vaccination with a higher frequency of 168 
memory CD8+ T cells coexpressing PD-1 and TIGIT (Figure 3A), and 169 
coexpressing CD27 and CD57 (Figure 3B). Changes in the population of CD8+ T 170 
cell exhibiting markers of activation were also observed as memory HLA DR+ 171 
CD38- CD8+ T cells were increased in the vaccine group (Figure 3C) without any 172 
modification of the memory CD4+ T cells (Figure 3D). No change was observed 173 
in the different CD4+ T cell subsets, including Treg or CD32a+ expressed on 174 
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CD4+ T cell HIV reservoir (not shown).   175 
 176 
Analytical Treatment Interruption 177 
ATI was proposed in both arms to individuals with plasma HIV RNA < 50 178 
copies/ml at week 36. Eighty-nine participants (n=32 (91%) and 57 (90%) in 179 
placebo and vaccine groups, respectively) started ATI according to study 180 
protocol and were followed until week 48, the final study end point. Sixty-five 181 
participants (n=23 (66%) and 42 (67%) in placebo and vaccine groups, 182 
respectively) resumed ART according to the study protocol at week 48. Eighteen 183 
participants (n=7 (20%) and 11 (17%) in placebo and vaccine groups, 184 
respectively) resumed ART before week 48 for participants or doctors’ decisions. 185 
Two participants from each group resumed ART after week 48, and two 186 
participants from the vaccine group did not resume ART at the end of the follow 187 
up after week 48. Figure 4A shows longitudinal evolution of HIV plasma viral 188 
loads (VL) in the two study arms during the ATI period. The maximum level of 189 
viral load was observed at week 42 in both groups. mITT analysis did not show 190 
any significant differences between groups in terms of maximum observed (peak) 191 
viral load: median peak VL (Q1;Q3) between weeks 36-48 were 5.26 (4.58;7) 192 
and 5.15 (4.73;7) in placebo and vaccine groups, respectively (P=0.9). The 193 
frequency of participants with VL below 10 000 copies/ml at week 48, defined as 194 
the virological success, was 50% and 44% in placebo and vaccine groups, 195 
respectively. In total, seventy-one patients met this predefined success criterion 196 
of the strategy without any significant difference between groups: 25 and 46 in 197 
placebo and vaccine groups, respectively (Table 2). 198 
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The kinetics of the peak of VL looks slightly different between groups having 199 
experienced ATI. At week 40, the maximum peak of VL was observed in 44% 200 
and 28% of participants in the placebo and vaccine groups, respectively 201 
(P=0.27). They were 8% and 20% at week 44, respectively (Table 2). At the end 202 
of the ATI phase (week 48), two participants from the vaccine group did not 203 
resume ART because of plasma VL below 50 copies/ml. These participants had 204 
an initial VL rebound at week 42 and 44, and then exhibited a spontaneous 205 
suppression of viremia which remained undetectable without ART at the end of 206 
the study. Among the 91 participants restarting cART, 75 (31 and 44 in placebo 207 
and vaccine group, respectively) participants suppressed viremia (<50 copies/ml) 208 
at W74. 209 
Figure 4B shows patterns of CD4+ T cell changes in participants during the ATI 210 
period. The evolution was similar in both groups of participants with a nadir 211 
(median, IQR) at week 44 of 657 cells/mm3 (556-832) and 661 (584-930) in 212 
placebo and vaccine groups, respectively. CD4+ T cell counts remain similar in 213 
both groups at the end of the study and after resuming ART at week 48.  214 
 215 
Relationship between polyfunctionality of HIV-specific T cell responses and 216 
viral parameters following ATI 217 
A principal component analysis (PCA) was conducted to illustrate the 218 
interrelationships between vaccine-induced T cell responses measured by ICS 219 
before ATI (polyf CD4, polyf CD8) and viral parameters during ATI.  220 
Figure 5A is a projection of variables on the first two axes. The first principal 221 
component (x-axis) represented 59% of the variability while the second principal 222 
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component represented 21%. All immunological variables were on the right side 223 
of the figure, illustrating their trend to be positively correlated. The y-axis allowed 224 
to differentiate the CD8+ T cell responses (top) and the CD4+ T cell responses 225 
(bottom). Results showed that maximal viral load, viral load slope and viral load 226 
AUC were projected at the opposite direction of the immune markers, indicating a 227 
trend towards negative correlations between the magnitude of viral load after ATI 228 
and T cell responses before ATI. In Fig. 5B, the representation of the patients on 229 
the PCA illustrates the poor immunological status of some patients (left side) and 230 
the CD4+ and CD8+ T cell-oriented response of the others (middle right). 231 
Vaccinated participants seemed to be slightly more numerous on the right part of 232 
the plan (as shown by the distribution blue curve on the top) corresponding to 233 
good responders, while those who were on the left part exhibited poorer 234 




Ninety-eight individuals received at least one injection, 93 received all injections. 239 
The majority of participants (96%) experienced at least one Adverse Events (AE) 240 
being transient (median duration 15 days, IQR 3-62). As shown in Table 3, most 241 
of the AE were grade 1 or 2 and there were no marked differences between 242 
arms. Among 15 Serious Adverse Events (SAE) (Table 4), one was possibly 243 
related to the GTU®-Multi-HIV B vaccine (arthritis) and one to the research: 244 
secondary HIV transmission during the ATI period confirmed by phylogenetic 245 
analysis of the HIV in the placebo arm (11). Primary infection-like symptoms, 246 
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usually mild, were observed in 23% of the individuals after ATI. There was no 247 




In this study, we show that a therapeutic immunization strategy combining a DNA 252 
prime followed by a boost with long HIV lipopeptides is well tolerated in 253 
chronically HIV-1 infected individuals treated with cART. These safety data are 254 
consistent with previous studies in HIV-1 infected individuals and healthy 255 
volunteers who received each vaccine component individually (8, 12, 13) .  256 
This study comprised two phases, a vaccination period followed by an ATI phase 257 
of 12 weeks to evaluate both the immunogenicity and virologic efficacy of the 258 
vaccine strategy. 259 
At the end of the vaccination period, the immunogenicity of the vaccine strategy 260 
was clearly demonstrated. Vaccinees exhibited significant changes in the 261 
frequency and the functionality of HIV-specific T cell responses. However, these 262 
changes in the immune status of individuals did not translate into any differences 263 
in the kinetics and magnitude of viral rebound following ATI. Consistently, we 264 
found that the vaccine strategy did not impact significantly the levels of cellular 265 
HIV-DNA measured before ATI (14). Nevertheless, integrative analysis of 266 
virological and immunological parameters showed a trend toward an association 267 
between good vaccine responders and a lower viral load after ATI, while 268 
individuals with poorer immunological responses (being vaccinated or not) 269 
exhibited a higher maximum viral load.  270 
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These findings might have important implications in the design and evaluation of 272 
future studies testing immunological interventions aimed at sustainably control 273 
viral replication without cART.  274 
 275 
The rationale to combine a DNA GTU prime and HIV long lipopeptides was 276 
based on previous results obtained with each individual vaccine component. 277 
Administration of DNA GTU in cART naïve individuals resulted in a modest, but 278 
significant, decrease of plasma HIV viral load (up to 0.5 log10 copies/ml) in a 279 
large therapeutic study performed in South African individuals (5). Previous 280 
therapeutic vaccine studies centered around HIV lipopeptides provided also 281 
encouraging results (7, 8). Combination of ALVAC/HIV lipopeptide and IL-2 282 
preceding ATI in chronically HIV-1 infected patients resulted in a greater chance 283 
to maintain a viral load during a 24 weeks ATI period (HIV RNA below 10 000 284 
copies/ml as predefined in the present study) compared to individuals from a 285 
control arm (12, 15). In a recent non randomized vaccine study, we showed that 286 
vaccination with ex vivo generated Dendritic Cells (DC) loaded with HIV-287 
lipopeptides (the Dalia trial) elicited strong CD4+ and CD8+ T cell responses 288 
associated with a control of viral replication following ATI in chronically HIV-1 289 
infected individuals (16). In these two previous studies, we found a correlation 290 
between vaccine elicited responses and the magnitude of viral replication or the 291 
frequency of individuals maintaining plasma HIV viral load below a predefined 292 
threshold following ATI (12, 15–18).  293 
 294 
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Here, the combination of these two vaccine components in a prime boost 295 
strategy was also supported by the sharing of several HIV T-cell epitopes in 296 
common, raising the hypothesis of a stronger induction of HIV-specific T cell 297 
responses. Indeed, immunogenicity analysis showed a significant expansion of 298 
functional T-cell responses (producing at least two cytokines) against HIV-1 Gag, 299 
Env and Pol antigens for CD4+ T cells while CD8+ T cells were directed against 300 
Env, Pol, Nef but not Gag antigens. Despite this broad repertoire, these 301 
responses did not impact significantly HIV replication throughout the 12-weeks of 302 
ATI. The failure to show an association between vaccine immunological efficacy 303 
and the kinetics of viral rebound raises several questions about the repertoire, 304 
functionality of these responses and the immunological context following 305 
vaccination. In depth analysis and epitope mapping of T-cell responses elicited 306 
by the DC-based vaccine delivering HIV lipopeptides revealed an inverse 307 
correlation between the functionality of CD4+ T cell responses (production of IL-2 308 
and IL-13), the repertoire of these responses directed against HIV Gag, Nef and 309 
Pol dominant epitopes, and the magnitude of viral rebound (17). These results 310 
are supported by several previous studies showing that robust HIV-1-specific T 311 
cell responses are associated with a better control of infection in LTNP (19). In 312 
the present study we did not investigate the precise repertoire of CD4+ T cell 313 
responses against individuals HIV epitopes. Whether the lack of antiviral effect of 314 
HIV-specific CD4+ T cell responses to vaccine regimen containing HIV 315 
lipopeptides delivered through IM route, as compared to DC delivery, could be 316 
explained by a difference in the immune profile (cytokine pattern) or repertoire of 317 
vaccine elicited CD4+ T-cell responses warrants further analyses.   318 
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We also show that the vaccine regimen elicited expansion of memory CD8+ T cell 320 
responses. Surprisingly, responses against Gag epitopes contained in the DNA 321 
GTU and Lipopeptide sequences were not amplified. Several teams, including 322 
our group, have shown the importance of CD8+ T cell responses to Gag in the 323 
control of HIV (17). Our results, from a subgroup of individuals, show also 324 
changes in the population of CD8+ T cell exhibiting markers of activation 325 
(increase of memory HLA DR+ CD38- CD8+ T cells in the vaccine group) and 326 
more importantly markers of exhaustion (TIGIT and PD-1) and senescence 327 
(CD57), which might indicate the low capacity of these cells to control viral 328 
replication. These inhibitory immune receptors have been previously shown to 329 
regulate antiviral and antitumor CD8+ T cell effector function in mice model of 330 
LCMV and in human with advanced melanoma (20–22). It has been shown that 331 
TIGIT and PD-1 blockade additively increased proliferation, cytokine production, 332 
and degranulation of tumor antigen-specific CD8+ T cells. One limitation of this 333 
observation is that we did not look at the expression of these markers on HIV-334 
specific CD8+ T cells. However, as already described in cancer patients, we 335 
cannot rule out that these specific CD8+ T cells would exhibit a low killing 336 
capacity of HIV infected cells (20). Regarding the design of future studies, these 337 
results underscore the need to include functional killing assays in the evaluation 338 
of the efficacy of vaccine trials (23). 339 
 340 
One intriguing question, beyond the results of this trial, is why despite the 341 
capability of eliciting strong immune responses, several candidate vaccines 342 
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tested showed disappointing results and failed to control HIV replication in cART-343 
free individuals. We, and others, have already raised the hypothesis that the 344 
balance between inflammatory responses and activation of effector T cells 345 
seems crucial in this setting (24). The deleterious association of persistent 346 
inflammation signature after vaccination with the immune response to vaccine 347 
has been reported for several vaccine platforms (25, 26), including HIV (24). 348 
Recently, integrative analysis of a large set of arrays (T-cell responses, cytokine 349 
production, blood transcriptomic changes) evaluating immune responses in 350 
individuals receiving DC/HIV lipopeptide vaccine showed that inflammatory 351 
pathways related to Toll-Like Receptor signaling were associated with a poorer 352 
immune response to vaccination and poorer viral control after ATI (24). The 353 
similar involvement and impact of these pathways in responses to other vaccines 354 
indicates a potential broad mechanism driving the immune response to vaccine. 355 
Likely these data underscore the need to carefully investigate, besides the profile 356 
of effector specific T cells, the kinetics of inflammatory responses in future 357 
vaccine studies. Furthermore, these results point out the need to develop further 358 
strategies combining vaccines with adjuvants and/or immunomodulators (3).  359 
 360 
The lack of immune correlates, or robust markers, predicting virologic control 361 
implies that a period of antiretroviral treatment interruption remains necessary to 362 
assess the efficacy of immune interventions in HIV-infected patients. Our study 363 
comprised a 12-weeks ATI period and an arbitrary threshold of plasma viral load 364 
defining the success of the strategy (i.e: frequency of individuals maintaining 365 
plasma viral load below 10 000 copies/ml). One month following cART 366 
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interruption, the maximum peak of plasma viral load concerned a higher 367 
percentage of placebo as compared to vaccinees (44% and 28% of participants, 368 
respectively). At the end of the ATI phase (week 48), two participants from the 369 
vaccine groups maintained a suppressed viral load below 50 copies/ml and 370 
remained without cART at week 74. Interestingly these participants had an initial 371 
VL rebound at week 42 and 44 which makes unlikely that these two subjects 372 
were elite HIV controllers. However, we were unable to demonstrate the efficacy 373 
of vaccine regimen in an intent-to-treat analysis and according to the predefined 374 
criteria of success. This underscores the added value of the comparison to a 375 
well-controlled placebo group (4) to limit the risk of misinterpreting results. The 376 
decision to propose ATI to individuals receiving placebo should be carefully 377 
balanced by the risk to miss the demonstration of efficacy or to erroneously 378 
conclude on existing efficacy of an immune intervention. Thus, the large 379 
heterogeneity of previous immunotherapeutic trials in terms of ATI duration, 380 
presence of a control group, threshold criteria for resuming cART, timeline of 381 
virologic evaluation might hinder the capacity to identify promising strategies. For 382 
example, the use of a conservative criterion for resuming cART, such as plasma 383 
viremia above 1 000-2 000 copies/ml, risks missing important positive effects of 384 
immune interventions on viral control (27). Likely, the recent consensus report on 385 
recommendations to optimize ATI strategies and to mitigate the risks for 386 
participants will help to better design future studies. 387 
 388 
In order to minimize the risks for participants undergoing ATI, in our trial we used 389 
strict safety criteria for resuming cART before the end of the 12-week period of 390 
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ATI, such as a confirmed >30% decline in CD4+ T cell count, an absolute CD4+ T 391 
cell count <350 cells/mm3, or the development of acute retroviral syndrome. 392 
Globally the strategy was well tolerated and no individuals reached these safety 393 
criteria for resuming cART.  394 
However, despite strong measures of counseling, ATI was associated with a 395 
secondary transmission to a sex partner of one participant from our study (11). 396 
This observation led our group to propose PrEP in our future HIV cure trial in 397 
France (28) but also at the European level (EHVA T02 trial NCT04120415; (29)). 398 
Although PrEP may mitigate the risk of secondary transmission, this strategy 399 
should be associated with strong counseling and additional measures of 400 
prevention because of the lack of clear data on the efficacy of PrEP against viral 401 
rebound to high levels of viremia following ATI. It would be also essential to 402 
closely monitor plasma viral load in participants during the ATI period and to 403 
adapt PrEP drugs to the resistant profile to the participant’s virus. 404 
 405 
In conclusion, the prime boost regimen tested in this study was designed to 406 
maximize the immune response and to evaluate its virologic efficacy in a well-407 
controlled design trial including a long-term ATI period. This study adds to the list 408 
of previous therapeutic vaccine trials showing that despite eliciting strong 409 
immune responses, no association to a long-term control of viremia was 410 
demonstrated. However, several lessons were learned from these results 411 
pointing out the urgent need to combine these vaccine strategies with other 412 
immune-based interventions. 413 
  414 
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MATERIALS AND METHODS 415 
 416 
Study design and participants 417 
The VRI02 ANRS 149 LIGHT trial is a phase II randomized, placebo-controlled, 418 
double-blinded, multicenter trial evaluating the safety and immunogenicity of a 419 
prime-boost vaccine strategy using a recombinant DNA prime vaccine (GTU®-420 
MultiHIV B clade) followed by a boost vaccination by a lipopeptide vaccine (HIV-421 
LIPO-5) in HIV-infected patients while on cART. Eligible patients were 422 
asymptomatic HIV-1-infected adults with CD4+ T-cell counts >600 cells/μL, 423 
plasma HIV RNA <50 copies/mL at screening and within the previous 6 months 424 
while on cART and were recruited in 18 hospitals in France. All study participants 425 
provided written informed consent before participation. The protocol was 426 
approved by the ethics committee of Ile de France 5 (Paris-Saint-Antoine) and 427 
authorized by the French regulatory authority (ANSM). The study is registered at 428 
www.ClinicalTrials.gov (NCT01492985) and EudraCT: 2009-018198-30. 429 
 430 
Randomization and masking 431 
Participants were randomized in a 1:2 ratio to receive either placebo or active 432 
vaccine. Randomization was done centrally one week before the first vaccination 433 
via the electronic case report software (Ennov clinical® software), on the basis of 434 
a randomization list generated by the unblinded statistician (CMG-EC, Inserm 435 













DNA GTU MultiHIV and HIV LIPO-5 have been described elsewhere (5–7). 440 
Briefly, GTU®-MultiHIV B clade, developed by FIT Biotech, encodes for a 441 
MultiHIV antigen (synthetic fusion protein built up by full-lenght polypeptides of 442 
Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, 443 
reverse transcriptase (RT) and envgp160 regions of the HAN2 HIV-1 B clade. 444 
HIV-LIPO-5 vaccine consisted in 5 long HIV peptides from (Nef 66-97; Nef 116-445 
145; Gag 17-35; Gag 253-284 and Pol 325-355) to which lipid tail are covalently 446 
bound. These lipopeptides which cover HIV epitopes binding to > 90% of HLA 447 
molecules, permit presentation of CD4+ and CD8+ T cell epitopes as well as 448 
generation of humoral immunity (17). 449 
The DNA GTU MultiHIV at a dose of 1 mg or placebo priming vaccinations were 450 
administered IM using a biojector at study weeks 0, 4 and 12. HIV-LIPO-5 451 
boosts, at a dose of 2.5 mg (0.5 mg of each lipopeptide) or placebo were given at 452 
weeks 20 and 24 (Figure 1A). For immunological analysis, PBMC samples were 453 
collected at entry (W0), four weeks following the last DNA GTU prime (W16) and 454 
the last LIPO-5 boost (W28), W48 (final end point) and W74. A cART interruption 455 
between W36 and W48 was proposed to individuals who had HIV-1 RNA <50 456 
copies/mL and CD4+ T-cell counts >600 cells/μL. Clinical, immunological (CD4+ 457 
and CD8+ T cell counts) and virological (HIV viral load) follow-up was performed 458 
every 15 days for 2 months during ATI, then monthly. cART has to be resumed at 459 
W48 but could be resumed at any time according to the following criteria: (i) if the 460 
patients or their doctors wished so; (ii) if CD4+ T-cell count was <350 cells/μL at 461 
two consecutive measurements 2-weeks apart; and (iii) in the case of occurrence 462 
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of an opportunistic infection or a serious non-AIDS defining event. Patients were 463 
followed until W74 for final safety evaluation after resuming cART.  464 
 465 
Intracellular cytokine staining (ICS) assay 466 
Cell functionality was assessed by ICS, with Boolean gating to examine vaccine-467 
induced HIV-1-specific CD4+ and CD8+ T cell responses after stimulation with 3 468 
different HIV 15-mer peptide pools (1 pool Gag, 1 pool Pol/Env and 1 pool Nef 469 
peptides, JPT Peptide Technologies GmbH, Berlin, Germany). SEB-stimulated 470 
and unstimulated cells were used as positive and negative control, respectively. 471 
The flow cytometry panel included a viability marker, CD3, CD4 and CD8 to 472 
determine T-cell lineage, and IFN-γ, TNF-α, and IL-2 antibodies. Data were 473 
acquired on a LSRFortessa 4-laser (488, 640, 561 and 405 nm) cytometer (BD 474 
Biosciences) and analyzed using FlowJo software version 9.9.4 (Tree Star inc.). 475 
 476 
Mass cytometry staining and analyses 477 
In a subpopulation of patients from both groups selected among those presenting 478 
an ICS response, a mass Cytometry (CyTOF) analysis was performed at weeks 479 
0 and 28. PBMC were thawed, rested and then stained using metal-conjugated 480 
antibodies according to the CyTOF manufacturer’s instructions (Fluidigm, San 481 
Francisco, CA). Cell viability staining was performed using the Cell-IDTM-103 Rh 482 
Intercallator at a final concentration of 1 µM that was incubated with PBMC for 15 483 
minutes. PBMC from an individual donor were treated in parallel and multiplexed 484 
for staining and mass cytometry analysis to limit sample variation due to sample 485 
preparation and analysis. Multiplexed week 0 and week 28 PBMC were stained 486 
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for 20 minutes with either anti-CD45 89 Y or anti-CD45 194 Pt isotopes, 487 
respectively, and then washed with CSM buffer (PBS, 0.5% BSA, 0.02% sodium 488 
azide, all from Sigma) before combining the two samples. Pooled samples 489 
containing 2-4x106 cells were stained for 30 minutes using a cocktail of 490 
antibodies for cell surface markers in a total volume of 50 µl (Table 5). Cells were 491 
subsequently washed with CSM and PBS, fixed with 2.4% formaldehyde 492 
(Thermo Fisher) in PBS for 5 minutes and then resuspended in DNA-intercalation 493 
solution (PBS, 1 μM Ir-Intercalator, 1% formaldehyde, 0.3% saponin) before 494 
storage at 4°C until analysis. For CyTOF analysis, cells were washed 3 times 495 
with MilliQ water and resuspended at 0.5x106 cells/ml in 0.1% EQ™ Four 496 
Element Calibration Beads solution (Fluidigm). Samples were normalized for the 497 
EQ™ bead intensities using the matlab normalizer software to limit inter analysis 498 
staining intensities. Data were processed and analyzed with cytobank. Since W0 499 
and W28 samples for a given donor were multiplexed and stained in parallel, the 500 
relative changes in marker intensities were determined using the W28/W0 ratio 501 
for the indicated gated positive populations. 502 
 503 
Study endpoints 504 
The primary endpoint was the maximum observed plasma HIV-1 RNA load (in 505 
log10 copies/mL) during the ATI period between W36 and W48. Participants not 506 
having interrupted cART at W36, or having resumed their treatment before W48, 507 
were imputed with the maximum plasma HIV-1 RNA load observed among all the 508 
participants during the ATI. The delay to the maximum plasma viral load was also 509 
described in participants having experienced the ATI between W36 and W48. 510 
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Clinical and virological secondary endpoints were as follows: the frequency of 511 
clinical and biological adverse events occurring during the trial; CD4+ T cell 512 
counts at W40, W44, W48, W74; HIV-1 RNA loads at W40, W44, W48, W74; the 513 
virological success, assessed as the percentage of participants with plasma 514 
HIV-1 RNA load below 10 000 copies/mL at W48 considering virological failure 515 
for participants not having interrupted cART at W36; proportion of participants 516 
who reinitiated ARTs after W36; proportion of participants with CD4+ T cell 517 
counts < 350/mm3. 518 
Secondary immunological end points were ICS based on the boolean and the 519 
marginal percentages of cells producing IFN-γ, IL-2 and TNF-α per T cell 520 
population (CD3+CD4+ and CD3+CD8+) after HIV stimulation (Gag, Pol/Env, Nef 521 
and total HIV) with background subtraction (negative values obtained after 522 
removing background were imputed to zero). The percentages of cells producing 523 
at least one cytokine among IFN-, IL-2 and TNF-α and polyfunctional cells (cells 524 
producing at least two or three cytokines) were also described.  525 
 526 
Statistical analysis  527 
The sample size calculation was based on the assumption that a reduction by at 528 
least 0.7 log10 copies/mL in plasma HIV-1 RNA level at the end of the ATI in the 529 
vaccinated group compared to the placebo group (standard deviation of the viral 530 
load at the end of the interruption estimated at 1.0 log10 copies/mL in the 531 
Window/ANRS 106 trial). With a two-sided type I error of 5% and a power of at 532 
least 90% (Wilcoxon-rank test), the targeted number of participants was 35 in the 533 
placebo group and 70 in the vaccine group. 534 
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All efficacy and safety analyses were carried out as modified intention to treat 535 
(mITT), in which participants who received no vaccine dose were excluded from 536 
the analysis. The immunological analyses were based on the per protocol 537 
population defined as exclusion from the analyses of participants with any 538 
discontinuation regarding either the vaccine therapy or the ATI. Quantitative and 539 
qualitative variables were respectively described by median and inter-quartile 540 
range and by frequency and proportion.  541 
The primary endpoint expressed as the maximal plasma viral load during the ATI 542 
was compared between the placebo and the vaccine groups with the two-sided 543 
Wilcoxon-rank test. The immune ICS responses were compared between W0 544 
and W28 in each arm using the Wilcoxon signed-rank test. A principal 545 
component analysis across ICS responses at W28 (log-transformed marginal % 546 
of positive cells for IFN-γ, IL-2, TNF-α, per T cell population, CD4+ and CD8+ 547 
respectively) was performed with a projection of highest viral load during ATI, 548 
viral load slope, time to rebound and viral load AUC as supplementary variable.  549 
Statistical analyses were performed using SAS (version 9.3 or higher, SAS 550 
Institute, Cary, NC, USA) and R (version 3.6.0, The R Foundation for Statistical 551 
Computing, Vienna, Austria). Tests with a two-sided P value of <.05 were 552 
considered statistically significant. 553 
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Figure legends 736 
 737 
Figure 1: Trial design. (A) Schematics of study design. Blue arrows indicate 738 
time of DNA GTU-MultiHIV B or placebo administrations. Red arrows indicate 739 
time of HIV LIPO-5 or placebo administrations. ART, antiretroviral therapy; ATI, 740 
analytical treatment interruption; (B) Consolidated Standards of Reporting Trials 741 
(CONSORT) flow diagram for the trial. CONSORT diagram delineates the study 742 
enrollment of 103 participants who underwent randomization to the placebo or 743 
vaccine groups.  744 
 745 
Figure 2: Functional profile of CD4+ and CD8+ T cell responses. Production 746 
of IL-2, IFN-𝛾 and TNF-α as measured by intracellular cytokine staining (ICS) 747 
using multiparametric flow cytometry after cell stimulation before (W0) and after 748 
vaccination (W28) in placebo (red) and therapeutic vaccine (blue) groups: (A) 749 
HIV-specific CD3+CD4+ T cell frequency; (B) HIV-specific CD3+CD8+ T cell 750 
frequency; (C) Heatmap of P values between W28 and W0 of CD3+CD4+ and 751 
CD3+CD8+ marginal responses against Gag, Pol/Env, Nef and sum of HIV 752 
peptides (Total HIV); (D) Frequency of HIV-specific CD3+CD4+ T cells producing 753 
1, 2 or 3 cytokines in the vaccine group at W0 (light grey) and W28 (dark grey); 754 
(E) Frequency of HIV-specific CD3+CD8+ T cells producing 1, 2 or 3 cytokines in 755 
the vaccine group at W0 (light grey) and W28 (dark grey); (F) Heatmap of P 756 
values between W28 and W0 of CD3+CD4+ and CD3+CD8+ polyfunctionality 757 
responses against Gag, Pol/Env, Nef and total HIV peptides. 758 
 759 
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Figure 3: CyTOF phenotyping. Ratio of memory CD8+ T cells at W28 compared 760 
to W0 for several subsets according to PD-1 and TIGIT (A), CD27 and CD57 (B), 761 
or HLA-DR and CD38 (C) in placebo (red) and therapeutic vaccine (blue) groups. 762 
Ratio of memory CD4+ T cells at W28 compared to W0 for HLA-DR and CD38 763 
(D) in placebo (red) and therapeutic vaccine (blue) groups. P-values were 764 
calculated using the Mann-Whitney test, where P=0.017 (*); P=0.0022 (**). 765 
 766 
Figure 4: Plasma HIV viral load and CD4+ T cell count changes throughout 767 
the study. (A) Levels of plasma HIV RNA in the placebo (red) and therapeutic 768 
vaccine (blue) groups before and after ATI (week 36-48); (B) CD4+ T cell count 769 
changes during the vaccination phase and following ATI in the placebo (red) and 770 
therapeutic vaccine (blue) groups before and after ATI (week 36-48). 771 
 772 
Figure 5: Integrative analysis of immune response to vaccine. Principal 773 
component analysis of ICS responses at W28. Log-transformed marginal CD4+ 774 
and CD8+ T cell responses at W28 were included as active variables; virological 775 
markers during ATI (highest viral load, viral load slope, viral load AUC, time to 776 
rebound) were included as supplementary variables. (A) Projection of variables; 777 
(B) Projection of individuals represented into placebo (red) and therapeutic 778 












Table 1: Baseline characteristics of study participants 782 
  Placebo   
(n = 35) 
Vaccine 
(n = 63) 
Total 
(n = 98) 
Age in years* 44 (38 ; 49) 46 (36 ; 51) 45 (38 ; 51) 
Male, n (%) 30 (86) 56 (89) 86 (88) 
Time since first positive serology (in 
years)* 
7 (5 ; 13) 8 (4 ; 14) 7 (4 ; 14) 
Nadir CD4+ (/mm
3
)* 390 (335 ; 502) 389 (332 ; 480) 390 (334 ; 480) 
CD4+ count at baseline (/mm
3
)* 844 (684 ; 1060) 840 (744 ; 1018) 842 (733 ; 1045) 
RNA zenith (log10 cp/ml)* 5.1 (4.8 ; 5.6) 5.0 (4.4 ; 5.4) 5.0 (4.5 ; 5.4) 
RNA at baseline (log10 cp/ml)* 1.6 (1.6 ; 1.6) 1.6 (1.6 ; 1.6) 1.6 (1.6 ; 1.6) 
* Median (Q1;Q3) 783 
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Table 2: Plasma HIV RNA values during ATI period 785 
  Placebo  
(n = 35) 
Vaccine 
(n = 63) 
Total 
(n = 98) 
P-value 
Maximum VL during ATI (log10 cp/ml)              
      Mean (SD) 5.39 (1.40) 5.42 (1.17) 5.41 (1.25)  
      Median (IQR) 5.26 (4.58 ; 7.00) 5.15 (4.73 ; 7.00) 5.16 (4.70 ; 7.00) 0.878 
      Range [min-max]  [1.60 – 7.00]  [1.60 - 7.00]  [1.60 - 7.00]  
ATI experience between W36 and W48, n (%) 25 (71) 46 (73) 71 (72)  
Time of maximum VL during ATI in 
participants having experienced ATI, n (%) 
       
      W38 2 (8) 3 (7) 5 (7)  
      W40 11 (44) 13 (28) 24 (34)  
      W42 8 (32) 15 (33) 23 (32)  
      W44 2 (8) 9 (20) 11 (15)  
      W48 2 (8) 6 (13) 8 (11)  
Maximum VL during ATI (log10 cp/ml)  
in participants having experienced ATI 
6.12   5.95   6.12    
Participants with VL below 10 000 cp/ml  
at W48*, n (%) 
       
      No 17 (50) 34 (56) 51 (54)  
      Yes 17 (50) 27 (44) 44 (46)  
* 4 participants did not resume ART at W36 and were considered in virological failure at W48 
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Table 3: Adverse events (AE) after W0 787 
  Placebo 
(n = 35) 
Vaccine 
(n = 63) 
Total 
(n = 98) 
Participants presenting at least one AE, n (%) 35 (100) 59 (94) 94 (96) 
Participants presenting at least one biological AE, n (%) 5 (14) 9 (14) 14 (14) 
Participants presenting at least one clinical AE, n (%) 35 (100) 59 (94) 94 (96) 
AE by maximal grade, n (%) 220    405   625    
      Grade 1 : Mild 84 (38) 217 (54) 301 (48) 
      Grade 2 : Moderate 123 (56) 170 (42) 293 (47) 
      Grade 3 : Severe 12 (5) 18 (4) 30 (5) 
      Grade 4 : Life threatening 1 (0) -  1 (0) 
SAE among all AEs, n (%)             
      No 213 (97) 397 (98) 610 (98) 
      Yes 7 (3) 8 (2) 15 (2) 
Median duration of AE (in days) (Q1;Q3) 24 (5;90) 12 (3;49) 15 (3;62) 
Participants presenting at least one AE related to vaccine, n (%) 12 (34) 34 (54) 46 (47) 
AE related to vaccine by maximal grade, n (%) 36  105  141  
 on A








      Grade 1 : Mild 19 (53) 85 (81) 104 (74) 
      Grade 2 : Moderate 17 (47) 19 (18) 36 (26) 
      Grade 3 : Severe -  1 (1) 1 (1) 
      Grade 4 : Life threatening -  -  -  
SAE among AE related to vaccine , n (%)       
      No 36 (100) 104 (99) 140 (99) 
      Yes -   1 (1) 1 (1) 
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Table 4: Description of severe adverse events (SAE) after W0 by System Organ Class (SOC) and preferred term (PT) 791 
SOC PT 
Placebo        
(n = 7) 
Vaccine 
(n = 8) 
Total 
(n = 15) 
Infections and infestations Peritonitis, n (%)  1 (14.3) .   1 (6.7) 
  Bacterial rectitis, n (%)  .   1 (12.5) 1 (6.7) 
  Transmitting the HIV infection, n (%)  1 (14.3) .   1 (6.7) 
Injury, poisoning and procedural 
complications  
Accident on the public highway, n (%)  .   1 (12.5) 1 (6.7) 
  Artery stenosis, n (%)  .   1 (12.5) 1 (6.7) 
  Toxicity of various agents, n (%)  .   1 (12.5) 1 (6.7) 
Musculoskeletal and connectives 
disorders  
Arthralgia, n (%)  1 (14.3) .   1 (6.7) 
  
Rheumatoïd arthritis, n (%)  .   1 (12.5) 1 (6.7) 
Heart disorders Congestive cardiomyopathy, n (%)  1 (14.3) .   1 (6.7) 
Reproductive system and breast 
disorders  
Benign prostatic hypertrophy, n (%)  1 (14.3) .   1 (6.7) 
Nervous system disorders Craniocerebral injuries + loss of 
consciousness, n (%)  
.   1 (12.5) 1 (6.7) 
Blood and lymphatic system disorders Iron deficiency anemia, n (%)  1 (14.3) .   1 (6.7) 
Psychiatric disorders Suicide, n (%)  1 (14.3) .   1 (6.7) 
 on A








Respiratory, thoracic and mediastinal 
disorders 
Pulmonary disorder, n (%)  .   1 (12.5) 1 (6.7) 













Table 5 : Overview of the mass cytometry panel 795 
M arker Iso t ope C lone Source V o l ( µ l)  per  50  µ l
CD45 89 Y HI30 Fluidigm 0.40
CD8 113 In RPA-T8 Biolegend 0.50
CD4 115 In RPA-T4 Biolegend 0.40
CCR6 141 Pr 11A9 Fluidigm 0.50
CD19 142 Nd HIB19 Fluidigm 0.80
ICOS 143 Nd C398.4A Biolegend 0.80
CD69 144 Nd FN50 Fluidigm 0.50
CD31 145 Nd WM 59 Fluidigm 0.60
IgD 146 Nd IA6-2 BD Biosciences 0.70
CD28 147 Sm L293 BD Biosciences 0.30
CD57 148 Nd G10F5 Biolegend 0.25
CCR4 149 Sm 205410 Fluidigm 0.75
OX40 150 Nd ACT35 Fluidigm 1.20
CD103 151 Eu Ber-ACT8 Fluidigm 0.80
CD21 152 Sm BL13 Fluidigm 0.50
TIGIT 153 Eu M BSA43 Fluidigm 0.60
TLR2 154 Sm TL2.1 Fluidigm 1.00
CD27 155 Gd L128 Fluidigm 0.50
CD11c 156 Gd 3.9 Biolegend 0.60
CCR7 159 Tb G043H7 Biolegend 0.30
CD14 160 Gd M 5E2 Fluidigm 0.97
CD1c 161 Dy L161 Biolegend 0.30
CD32a-APC 162 Dy APC003 Fluidigm 3.5/1.0
CXCR3 163 Dy G025H7 Fluidigm 0.60
CD45RO 165 Ho UCHL1 Fluidigm 0.36
CD38 167 Er HIT2 Fluidigm 0.30
CD40L 168 Er 24-31 Fluidigm 1.20
CD45RA 169 Tm HI100 Fluidigm 0.80
CD3 170 Er UCHT1 Fluidigm 0.40
LAG3 172 Yb BM S Biotechne 1.60
HLA-DR 173 Yb L243 Fluidigm 0.30
PD1 174 Yb EH12.2H7 Fluidigm 0.50
CXCR4 175 Lu 12G5 Fluidigm 0.35
CD127 176 Yb A019D5 Fluidigm 0.70
CD45 194 Pt HI30 Biolegend 0.50
CD16 209 Bi 3G8 Fluidigm 0.50
 796 
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